胶原蛋白攻防战:钟睒睒押注锦波生物,巨子联手汪建国

21世纪经济报道
30 Jun

当技术红利窗口急速收窄,昔日两大重组胶原“股王”却选择截然不同的突围之路:锦波生物借钟睒睒34亿元资本加码严肃医疗研发,巨子生物聚焦药械产品、经销渠道两手抓。  近日,国家药监局药品审评中心最新信息显示,陕西巨子生物"重组胶原蛋白冻干纤维"药械组合申请已于2025年6月13日获受理审批,标志着其核心布局正式冲刺药械赛道入场券。  巨头此行,并非领跑。锦波生物“重组Ⅲ型人源化胶原蛋白冻干纤维”早在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10